NABUMETONE Drug Patent Profile
✉ Email this page to a colleague
When do Nabumetone patents expire, and when can generic versions of Nabumetone launch?
Nabumetone is a drug marketed by Annora Pharma, Aurobindo Pharma Usa, Chartwell Molecules, Chartwell Rx, Copley Pharm, Epic Pharma Llc, Impax Labs Inc, Invagen Pharms, Lgm Pharma, Nostrum Labs Inc, Oxford Pharms, Sciegen Pharms Inc, and Watson Labs. and is included in thirteen NDAs.
The generic ingredient in NABUMETONE is nabumetone. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the nabumetone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nabumetone
A generic version of NABUMETONE was approved as nabumetone by CHARTWELL RX on February 25th, 2002.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NABUMETONE?
- What are the global sales for NABUMETONE?
- What is Average Wholesale Price for NABUMETONE?
Summary for NABUMETONE
| US Patents: | 0 |
| Applicants: | 13 |
| NDAs: | 13 |
| Finished Product Suppliers / Packagers: | 25 |
| Raw Ingredient (Bulk) Api Vendors: | 109 |
| Clinical Trials: | 8 |
| Patent Applications: | 5,754 |
| Drug Prices: | Drug price information for NABUMETONE |
| Drug Sales Revenues: | Drug sales revenues for NABUMETONE |
| DailyMed Link: | NABUMETONE at DailyMed |
See drug prices for NABUMETONE
Recent Clinical Trials for NABUMETONE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
| Federal University of São Paulo | Phase 4 |
| Region Syddanmark | N/A |
Pharmacology for NABUMETONE
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for NABUMETONE
US Patents and Regulatory Information for NABUMETONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annora Pharma | NABUMETONE | nabumetone | TABLET;ORAL | 090445-001 | Jan 12, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Lgm Pharma | NABUMETONE | nabumetone | TABLET;ORAL | 203166-002 | Aug 30, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sciegen Pharms Inc | NABUMETONE | nabumetone | TABLET;ORAL | 078420-002 | Sep 24, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | NABUMETONE | nabumetone | TABLET;ORAL | 075280-001 | Feb 25, 2002 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
